T1	Participants 141 156	cancer patients
T2	Participants 164 200	patients with venous thromboembolism
T3	Participants 437 523	patients on long-term therapy for acute venous thromboembolism who have active cancer.
T4	Participants 1285 1312	patients with active cancer
